# 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients

> **NCT01843348** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 612 (actual)

## Conditions studied

- Kidney Transplantation
- Renal Transplantation

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Tacrolimus
- **DRUG:** Cyclosporin A
- **DRUG:** Enteric Coated Mycophenolate Sodium (EC-MPS)
- **DRUG:** Mycophenolate mofetil (MMF)
- **DRUG:** Corticosteroids
- **DRUG:** Simulect

## Key facts

- **NCT ID:** NCT01843348
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-27
- **Primary completion:** 2016-03-23
- **Final completion:** 2016-03-23
- **Target enrollment:** 612 (ACTUAL)
- **Last updated:** 2017-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01843348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01843348, "12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01843348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*